| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
MWM is a creative apps publisher with a large ecosystem of creative and music apps for iOS and Android devices. They offer users infinite ways to achieve their creative potential through fun and innovative apps. MWM has become one of the most promising...
inav.net is a Lisbon, IA-based company in the Software and Internet sector.
Vyve Broadband is the local service provider youve been searching for, with the fastest internet, all-digital HD TV and unlimited nationwide calling.
PowerFile develops hybrid storage appliances for the long-term storage of digital content and assets.